Literature DB >> 21380780

Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review.

Orit Kaidar-Person1, Salem Billan, Abraham Kuten.   

Abstract

Salivary duct carcinoma (SDC) is a rare subtype of salivary gland carcinoma and is considered to be a high-grade aggressive tumor with morphological resemblance to ductal carcinoma of the breast. We present a case of a patient who suffered from metastatic SDC that was positive for human epidermal growth factor receptor-2 (HER-2) and attained complete objective response, as seen on PET-CT after combined treatment with paclitaxel, carboplatin, and trastuzumab.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21380780     DOI： 10.1007/s12032-011-9884-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  15 in total

1.  Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.

Authors:  Nicholas Robert; Brian Leyland-Jones; Lina Asmar; Robert Belt; Des Ilegbodu; David Loesch; Robert Raju; Elizabeth Valentine; Robert Sayre; Melody Cobleigh; Kathy Albain; Cecelia McCullough; Lea Fuchs; Dennis Slamon
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

Review 2.  Targeting HER2 in other tumor types.

Authors:  S Scholl; P Beuzeboc; P Pouillart
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

3.  Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression.

Authors:  A Skálová; V Kucerová; P Szépe; L Plank
Journal:  Pathol Res Pract       Date:  2001       Impact factor: 3.250

Review 4.  Systemic therapy in the palliative management of advanced salivary gland cancers.

Authors:  Scott A Laurie; Lisa Licitra
Journal:  J Clin Oncol       Date:  2006-06-10       Impact factor: 44.544

Review 5.  Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine.

Authors:  Robert Haddad; Marshall R Posner
Journal:  Clin Adv Hematol Oncol       Date:  2003-04

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study.

Authors:  Christopher J Johnson; Michelle B Barry; Mohammad A Vasef; Barry R Deyoung
Journal:  Appl Immunohistochem Mol Morphol       Date:  2008-01

8.  Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy.

Authors:  Vishad Nabili; Jesse W Tan; Sunita Bhuta; Joel A Sercarz; Christian S Head
Journal:  Head Neck       Date:  2007-10       Impact factor: 3.147

9.  Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry.

Authors:  A Skálová; I Stárek; T Vanecek; V Kucerová; L Plank; P Szépe; S Di Palma; I Leivo
Journal:  Histopathology       Date:  2003-04       Impact factor: 5.087

10.  Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study.

Authors:  Robert Haddad; A Dimitrios Colevas; Jeffrey F Krane; Dennis Cooper; Bonnie Glisson; Philip C Amrein; Linda Weeks; Rosemary Costello; Marshall Posner
Journal:  Oral Oncol       Date:  2003-10       Impact factor: 5.337
View more
  17 in total

1.  Salivary duct carcinoma: evaluation of treatment and outcome in a tertiary referral institute.

Authors:  Ann-Jean C C Beck; Peter J F M Lohuis; Abrahim Al-Mamgani; Laura A Smit; Willem M C Klop
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-05-21       Impact factor: 2.503

2.  Salivary duct carcinoma treated with cetuximab-based targeted therapy: A case report.

Authors:  Kenta Kawahara; Akimitsu Hiraki; Ryoji Yoshida; Hidetaka Arita; Yuichiro Matsuoka; Toshio Yamashita; Kan-Ichi Koga; Masashi Nagata; Akiyuki Hirosue; Daiki Fukuma; Hideki Nakayama
Journal:  Mol Clin Oncol       Date:  2017-04-21

3.  Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors.

Authors:  Nhu Thuy Can; Mark W Lingen; Heather Mashek; James McElherne; Renee Briese; Carrie Fitzpatrick; Annemieke van Zante; Nicole A Cipriani
Journal:  Head Neck Pathol       Date:  2017-07-05

4.  Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.

Authors:  Tatsuo Masubuchi; Yuichiro Tada; Shin-ichiro Maruya; Yoshiyuki Osamura; Shin-etsu Kamata; Kouki Miura; Chihiro Fushimi; Hideaki Takahashi; Daisuke Kawakita; Seiji Kishimoto; Toshitaka Nagao
Journal:  Int J Clin Oncol       Date:  2014-02-20       Impact factor: 3.402

5.  Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin.

Authors:  Juliann Chmielecki; Jeffrey S Ross; Kai Wang; Garrett M Frampton; Gary A Palmer; Siraj M Ali; Norma Palma; Deborah Morosini; Vincent A Miller; Roman Yelensky; Doron Lipson; Philip J Stephens
Journal:  Oncologist       Date:  2014-12-05

6.  Carcinoma ex-pleomorphic adenoma of the salivary glands has a high risk of progression when the tumor invades more than 2.5 mm beyond the capsule of the residual pleomorphic adenoma.

Authors:  Miguel Rito; Isabel Fonseca
Journal:  Virchows Arch       Date:  2015-12-05       Impact factor: 4.064

Review 7.  Systemic therapy in the management of metastatic or advanced salivary gland cancers.

Authors:  Aymen Lagha; Nesrine Chraiet; Mouna Ayadi; Sarra Krimi; Bassem Allani; Hela Rifi; Henda Raies; Amel Mezlini
Journal:  Head Neck Oncol       Date:  2012-05-04

8.  Complete Response to Trastuzumab-Based Chemotherapy in a Patient with Human Epidermal Growth Factor Receptor-2-Positive Metastatic Salivary Duct Carcinoma ex Pleomorphic Adenoma.

Authors:  Shigenori Kadowaki; Yasushi Yatabe; Hitoshi Hirakawa; Azusa Komori; Chihiro Kondoh; Yasuhisa Hasegawa; Kei Muro
Journal:  Case Rep Oncol       Date:  2013-09-10

9.  Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells.

Authors:  Laura Masuelli; Massimo Fantini; Monica Benvenuto; Pamela Sacchetti; Maria Gabriella Giganti; Ilaria Tresoldi; Paolo Lido; Florigio Lista; Federica Cavallo; Patrizia Nanni; Jeffrey Schlom; Andrea Modesti; Roberto Bei
Journal:  J Transl Med       Date:  2014-05-10       Impact factor: 5.531

10.  Hormone dependent metastatic salivary gland carcinoma: a case report.

Authors:  Abed Agbarya; Salem Billan; Haitam Nasrallah; Addie Dvir; Lior Soussan-Gutman; Orit Kaidar-Person
Journal:  Springerplus       Date:  2014-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.